Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18516079rdf:typepubmed:Citationlld:pubmed
pubmed-article:18516079lifeskim:mentionsumls-concept:C0014644lld:lifeskim
pubmed-article:18516079lifeskim:mentionsumls-concept:C0024314lld:lifeskim
pubmed-article:18516079lifeskim:mentionsumls-concept:C0332835lld:lifeskim
pubmed-article:18516079lifeskim:mentionsumls-concept:C0687676lld:lifeskim
pubmed-article:18516079lifeskim:mentionsumls-concept:C1419875lld:lifeskim
pubmed-article:18516079lifeskim:mentionsumls-concept:C1515895lld:lifeskim
pubmed-article:18516079pubmed:issue3lld:pubmed
pubmed-article:18516079pubmed:dateCreated2008-8-13lld:pubmed
pubmed-article:18516079pubmed:abstractTextFatal problems encountered in allogeneic stem cell transplantation include EBV reactivation and post transplant lymphoproliferative disorders (PTLDs) with high mortality rates. We performed a retrospective analysis in all consecutive adult and pediatric EBV reactivations and PTLD during a period of 8.5 years. There were 26 patients with EBV reactivation/PTLD out of a total of 854 transplantations giving an overall incidence of 3.0%. Specifically, the incidence of EBV-PTLD was 1.3%, whereas that of EBV reactivation was 1.8%. Median age was 46.0 and 11.0 years in the adult and pediatric patients, respectively. There were high rates (54%) of concomitant bacterial, viral, fungal and parasitic infections at the time of EBV manifestation. Variable treatment regimens were applied including in most cases an anti-CD20 regimen often in combination with virustatic compounds, polychemotherapy or donor lymphocytes. The mortality rates were 9 of 11 (82%) in patients with EBV-PTLD and 10 of 15 (67%) in patients with reactivation. Only 7 of 26 patients (27%) are alive after a median follow-up of 758 days (range 24-2751). The high mortality rates of EBV reactivation and of EBV-PTLD irrespective of multimodal treatment approaches emphasize standardization and optimization of post transplant surveillance and treatment strategies to improve control of these often fatal complications.lld:pubmed
pubmed-article:18516079pubmed:languageenglld:pubmed
pubmed-article:18516079pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18516079pubmed:citationSubsetIMlld:pubmed
pubmed-article:18516079pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18516079pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18516079pubmed:statusMEDLINElld:pubmed
pubmed-article:18516079pubmed:monthAuglld:pubmed
pubmed-article:18516079pubmed:issn0268-3369lld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:ZanderA RARlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:KabischHHlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:AyubMMlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:MutaHHlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:ErttmannRRlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:PetersenLLlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:SobottkaIIlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:BachetWWlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:KroegerNNlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:LellekHHlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:ZabelinaTTlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:OcheniSSlld:pubmed
pubmed-article:18516079pubmed:authorpubmed-author:WolschkeCClld:pubmed
pubmed-article:18516079pubmed:issnTypePrintlld:pubmed
pubmed-article:18516079pubmed:volume42lld:pubmed
pubmed-article:18516079pubmed:ownerNLMlld:pubmed
pubmed-article:18516079pubmed:authorsCompleteYlld:pubmed
pubmed-article:18516079pubmed:pagination181-6lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:meshHeadingpubmed-meshheading:18516079...lld:pubmed
pubmed-article:18516079pubmed:year2008lld:pubmed
pubmed-article:18516079pubmed:articleTitleEBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.lld:pubmed
pubmed-article:18516079pubmed:affiliationDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.lld:pubmed
pubmed-article:18516079pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18516079pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18516079lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18516079lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18516079lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18516079lld:pubmed